Natera (NTRA) saw a 34.66% revenue increase in Q3 2025, with stock up nearly 70% since then. Druckenmiller holds $517.4M in Natera. Insmed (INSM) revenue surged 52.36% YoY in Q3 2025, with stock climbing from $25 to $189 since Q2 2024. Teva (TEVA) rallied over 300% since June 2023.

Druckenmiller is heavily invested in Natera, Insmed, and Teva, with NTRA being his biggest holding. NTRA stock has gained over 500% since 2023, with strong revenue growth and analyst expectations of positive EPS by 2028. Insmed focuses on pulmonary conditions, with a 52.36% revenue increase in Q3 2025.

Teva Pharmaceuticals, the largest producer of generic medicines, has rallied over 300% since June 2023. Druckenmiller has been accumulating shares in Teva since Q3 2024, betting on its growth potential. Retirement planning is crucial, with many finding they can retire earlier than expected after answering three key questions.

Read more at Yahoo Finance: Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks